Catalyst Pharmaceuticals, Inc. $CPRX Holdings Lifted by WINTON GROUP Ltd

WINTON GROUP Ltd grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 546.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 353,529 shares of the biopharmaceutical company’s stock after purchasing an additional 298,862 shares during the period. WINTON GROUP Ltd’s holdings in Catalyst Pharmaceuticals were worth $8,251,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Lifestyle Asset Management Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 3.4% in the fourth quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 553 shares in the last quarter. Globeflex Capital L P boosted its holdings in shares of Catalyst Pharmaceuticals by 0.5% in the fourth quarter. Globeflex Capital L P now owns 292,208 shares of the biopharmaceutical company’s stock valued at $6,820,000 after acquiring an additional 1,529 shares in the last quarter. State of Wyoming boosted its holdings in shares of Catalyst Pharmaceuticals by 5.6% in the fourth quarter. State of Wyoming now owns 21,559 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 1,144 shares in the last quarter. AXQ Capital LP bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $405,000. Finally, One Capital Management LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 61.1% in the fourth quarter. One Capital Management LLC now owns 74,973 shares of the biopharmaceutical company’s stock valued at $1,750,000 after acquiring an additional 28,433 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $31.27 on Friday. The firm has a market cap of $3.83 billion, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The firm’s 50 day moving average price is $28.44 and its two-hundred day moving average price is $25.33.

Analyst Upgrades and Downgrades

CPRX has been the subject of several recent analyst reports. HC Wainwright cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $31.50 in a report on Thursday, May 28th. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $31.50 in a report on Friday, May 8th. Finally, Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).